Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes

Atherosclerosis

Volumn 206, Issue 2, 2009, Pages 540-545

  Lu, Lin ^a   Pu, Li Jin ^b   Zhang, Qi ^a   Wang, Ling Jie ^b   Kang, Sheng ^a   Zhang, Rui Yan ^a   Chen, Qiu Jing ^b   Wang, Ji Guang ^c   De Caterina, Raffaele ^d   Shen, Wei Feng ^a,b  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Shanghai Institute of Hypertension   (China)

^d UNIVERSITY OF CHIETI   (Italy)

Author keywords

Coronary artery disease; Endogenous secretory receptor for advanced glycation end products; Glycated albumin; Inflammation; Type 2 diabetes mellitus

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN; GLYCOSYLATED ALBUMIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LIPOPROTEIN A; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; ALBUMIN BLOOD LEVEL; ANGIOCARDIOGRAPHY; ARTICLE; CHINA; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE;

C-REACTIVE PROTEIN; CHINA; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INTERLEUKIN-6; MALE; RECEPTORS, IMMUNOLOGIC; SERUM ALBUMIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349525016     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.12.045     Document Type: Article

References (40)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
3. King H., Aubert R.E., and Herman W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21 (1998) 1414-1431
4. Schmidt A.M., Yan S.D., and Stern D.M. The dark side of glucose. Nat Med 1 (1995) 1002-1004
5. Ahmed N., and Thornalley P.J. Quantitative screening of protein biomarkers of early glycation, advanced glycation, oxidation and nitrosation in cellular and extracellular proteins by tandem mass spectrometry multiple reaction monitoring. Biochem Soc Trans 31 (2003) 1417-1422
6. Cohen M.P. Intervention strategies to prevent pathogenetic effects of glycated albumin. Arch Biochem Biophys 419 (2003) 25-30
7. Yan S.D., Chen X., Fu J., et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382 (1996) 685-691
8. Hofmann M.A., Drury S., Fu C., et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97 (1999) 889-901
9. Taguchi A., Blood D.C., del Toro G., et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405 (2000) 354-360
10. Schmidt A.M., Hori O., Chen J.X., et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96 (1995) 1395-1403
11. Basta G., Lazzerini G., Massaro M., et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105 (2002) 816-822
12. Naka Y., Bucciarelli L.G., Wendt T., et al. RAGE axis: animal models and novel insights into the vascular complications of diabetes. Arterioscler Thromb Vasc Biol 24 (2004) 1342-1349
13. Bunn H.F., Gabbay K.H., and Gallop P.M. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 200 (1978) 21-27
14. Schram M.T., Schalkwijk C.G., Bootsma A.H., et al. Advanced glycation end products are associated with pulse pressure in type 1 diabetes: the EURODIAB Prospective Complications study. Hypertension 46 (2005) 232-237
15. Bian Z.M., Elner V.M., Lukacs N.W., et al. Glycated human serum albumin induces IL-8 and MCP-1 gene expression in human corneal keratocytes. Curr Eye Res 17 (1998) 65-72
16. Hattori Y., Kakishita H., Akimoto K., et al. Glycated serum albumin-induced vascular smooth muscle cell proliferation through activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by protein kinase C. Biochem Biophys Res Commun 281 (2001) 891-896
17. Higai K., Shimamura A., and Matsumoto K. Amadori-modified glycated albumin predominantly induces E-selectin expression on human umbilical vein endothelial cells through NADPH oxidase activation. Clin Chim Acta 367 (2006) 137-143
18. Yonekura H., Yamamoto Y., Sakurai S., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370 (2003) 1097-1109
19. Park I.H., Yeon S.I., Youn J.H., et al. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol Immunol 40 (2004) 1203-1211
20. Koyama H., Shoji T., Yokoyama H., et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 25 (2005) 2587-2593
21. Katakami N., Matsuhisa M., Kaneto H., et al. Serum endogenous secretory RAGE levels are inversely associated with carotid IMT in type 2 diabetic patients. Atherosclerosis 190 (2007) 22-23
22. Tan K.C., Shiu S.W., Chow W.S., et al. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 49 (2006) 2756-2762
23. Yamagishi S., Adachi H., Nakamura K., et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 55 (2006) 1227-1231
24. Cohen M.P., Ziyadeh F.N., and Chen S. Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications. J Lab Clin Med 147 (2006) 211-219
25. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
26. Anderson M.M., Requena J.R., Crowley J.R., et al. The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 104 (1999) 103-113
27. Scanlon P.J., Faxon D.P., Audet A.M., et al. ACC/AHA guidelines for coronary angiography: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography) developed in collaboration with the Society for Cardiac Angiography and Interventions. Circulation 99 (1999) 2345-2357
28. Valensi P., Paries J., Brulport-Cerisier V., et al. Predictive value of silent myocardial ischemia for cardiac events in diabetic patients: influence of age in a French multicenter study. Diabetes Care 28 (2005) 2722-2727
29. Alpert J.S., Thygesen K., Antman E., et al. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36 (2000) 959-969
30. Pajunen P., Nieminen M.S., Taskinen M.R., et al. Quantitative comparison of angiographic characteristics of coronary artery disease in patients with noninsulin-dependent diabetes mellitus compared with matched nondiabetic control subjects. Am J Cardiol 80 (1997) 550-556
31. Pu L.J., Lu L., Xu X.W., et al. Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 5 (2006) 27
32. Falcone C., Emanuele E., D'Angelo A., et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25 (2005) 1032-1037
33. Tan K.C., Chow W.S., Tso A.W., et al. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. Diabetologia 50 (2007) 1819-1825
34. Cuccurullo C., Iezzi A., Fazia M.L., et al. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 26 (2006) 2716-2723
35. Arroyo-Espliguero R., Avanzas P., Cosin-Sales J., et al. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J 25 (2004) 401-408
36. Manginas A., Bei E., Chaidaroglou A., et al. Peripheral levels of matrix metalloproteinase-9, interleukin-6, and C-reactive protein are elevated in patients with acute coronary syndromes: correlations with serum troponin I. Clin Cardiol 28 (2005) 182-186
37. Yang J., Li X.P., Zhao S.P., et al. The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome. Clin Chim Acta 368 (2006) 183-187
38. Hung M.J., Cherng W.J., Cheng C.W., et al. Comparison of serum levels of inflammatory markers in patients with coronary vasospasm without significant fixed coronary artery disease versus patients with stable angina pectoris and acute coronary syndromes with significant fixed coronary artery disease. Am J Cardiol 97 (2006) 1429-1434
39. Shimoyamada H., Fan J., Watanabe T., et al. Accelerated atherosclerosis with apolipoprotein(a) and oxidized low-density lipoprotein deposition in acute rejection of transplanted kidney: analogous to atherosclerosis. Clin Transplant 16 Suppl 8 (2002) 35-39
40. De Caterina R., and Zimarino M. Coronary artery remodelling in atherosclerosis: unfortunately unpredictable. Eur Heart J 27 (2006) 1761-1763